Colchicine in primary biliary cirrhosis
โ Scribed by T. W. WARNES
- Book ID
- 108603017
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 611 KB
- Volume
- 5
- Category
- Article
- ISSN
- 0269-2813
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
The efficacy of colchicine combined with ursodeoxycholic acid (UDCA) and UDCA alone in the treatment of patients with nonadvanced primary biliary cirrhosis (PBC) was evaluated in a 2-year controlled study. Seventy-four patients with PBC who had been treated previously with UDCA (at least 8 months) b
Lymphocyte and monocyte function was investigated in eight patients with primary biliary cirrhosis and in age-matched and sex-matched controls. In three of the eight cirrhotic patients, two were in the late stage of the disease (stage 111) and concanavalin A-induced s u p pressor cell function was m
Primary biliary cirrhosis (PBC) is a chronic, progressive, cholestatic liver disease. Interleukin-lp (JL-lp) may play a role in the pathogenesis of PBC by contributing to altered immune function and fibrosis. Colchicine or methotrexate has some beneficial effects in the treatment of PBC, and also af
Primary biliary cirrhosis frequently progresses despite treatment with ursodeoxycholic acid (UDCA), the only approved therapy. Previous studies suggested that colchicine and methotrexate may improve biochemical tests of liver function, symptoms, and liver histology. The aim of the present study was